Seonix Bio has introduced SightScore, a clinical polygenic risk-testing service for primary open-angle glaucoma. Using a saliva test to examine 7 million genetic variants to estimate the risk of glaucoma development and progression, it can identify patients who are at high risk for the disease, allowing for early diagnosis and personalized treatment. The test also evaluates low-risk individuals for less frequent monitoring. 

Source: Ophthalmology Management